Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT00262522
First received: December 5, 2005
Last updated: February 3, 2012
Last verified: February 2012
Results First Received: July 9, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus Infections
Intervention: Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were enrolled at 131 sites in 19 countries.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 672 subjects randomized, 8 discontinued from the study prior to receiving study drug due to withdrawal of consent (3), acute illness (2), lost to follow-up (1), other (1), and required prohibited medication (1).

Reporting Groups
  Description
LPV/r 800/200 mg QD Tablet lopinavir/ritonavir 800/200 mg once daily (QD) tablet
LPV/r 800/200 mg QD SGC (Through Week 8) lopinavir/ritonavir 800/200 mg once daily (QD) soft gel capsule (SGC)
LPV/r 400/100 mg BID Tablet lopinavir/ritonavir 400/100 mg twice daily (BID) tablet
LPV/r 400/100 mg BID SGC (Through Week 8) lopinavir/ritonavir 400/100 mg twice daily (BID) soft gel capsule (SGC)

Participant Flow for 3 periods

Period 1:   Study Start Through 8 Weeks
    LPV/r 800/200 mg QD Tablet   LPV/r 800/200 mg QD SGC (Through Week 8)   LPV/r 400/100 mg BID Tablet   LPV/r 400/100 mg BID SGC (Through Week 8)
STARTED   167   166   166   165 
COMPLETED   163   161   155   160 
NOT COMPLETED   4   5   11   5 
Adverse Event                1                2                3                1 
Withdrawal by Subject                1                1                3                0 
Lost to Follow-up                1                2                3                2 
Noncompliance                0                0                2                2 
Death                1                0                0                0 

Period 2:   Study Start Through 48 Weeks
    LPV/r 800/200 mg QD Tablet   LPV/r 800/200 mg QD SGC (Through Week 8)   LPV/r 400/100 mg BID Tablet   LPV/r 400/100 mg BID SGC (Through Week 8)
STARTED   333 [1]   0 [2]   331 [1]   0 [3] 
COMPLETED   284   0   276   0 
NOT COMPLETED   49   0   55   0 
Adverse Event                16                0                10                0 
Withdrawal by Subject                10                0                11                0 
Lost to Follow-up                8                0                14                0 
Noncompliance                3                0                8                0 
Death                2                0                1                0 
Virologic failure                2                0                4                0 
Relocated, Needed to take twice daily                8                0                7                0 
[1] Number of subjects who started the study, not the number who completed the first 8 weeks.
[2] After Week 8, these subjects received the tablet formulation once daily through the end of study.
[3] After Week 8, these subjects received the tablet formulation twice daily through the end of study.

Period 3:   Study Start Through 96 Weeks
    LPV/r 800/200 mg QD Tablet   LPV/r 800/200 mg QD SGC (Through Week 8)   LPV/r 400/100 mg BID Tablet   LPV/r 400/100 mg BID SGC (Through Week 8)
STARTED   333 [1]   0 [2]   331 [1]   0 [3] 
COMPLETED   256   0   254   0 
NOT COMPLETED   77   0   77   0 
Adverse Event                20                0                16                0 
Withdrawal by Subject                15                0                13                0 
Lost to Follow-up                19                0                18                0 
Noncompliance                6                0                11                0 
Death                2                0                2                0 
Virologic failure                5                0                8                0 
Relocated, Needed to take twice daily                10                0                9                0 
[1] Number of subjects who started the study, not the number who completed the first 48 weeks.
[2] After Week 8, these subjects received the tablet formulation once daily through the end of study.
[3] After Week 8, these subjects received the tablet formulation twice daily through the end of study.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
LPV/r 800/200 mg QD Tablet lopinavir/ritonavir 800/200 mg once daily (QD) tablet
LPV/r 800/200 mg QD SGC (Through Week 8) lopinavir/ritonavir 800/200 mg once daily (QD) soft gel capsule (SGC)
LPV/r 400/100 mg BID Tablet lopinavir/ritonavir 400/100 mg twice daily (BID) tablet
LPV/r 400/100 mg BID SGC (Through Week 8) lopinavir/ritonavir 400/100 mg twice daily (BID) soft gel capsule (SGC)
Total Total of all reporting groups

Baseline Measures
   LPV/r 800/200 mg QD Tablet   LPV/r 800/200 mg QD SGC (Through Week 8)   LPV/r 400/100 mg BID Tablet   LPV/r 400/100 mg BID SGC (Through Week 8)   Total 
Overall Participants Analyzed 
[Units: Participants]
 167   166   166   165   664 
Age 
[Units: Years]
Mean (Standard Deviation)
 38.7  (9.80)   38.2  (9.63)   38.3  (9.69)   39.5  (10.31)   38.7  (9.85) 
Gender 
[Units: Participants]
         
Female   36   31   39   38   144 
Male   131   135   127   127   520 
CD4+ T Cell Count [1] 
[Units: Cells/mm3]
Mean (Standard Deviation)
 209.9  (125.10)   222.6  (127.37)   226.4  (136.64)   202.9  (139.57)   215.5  (132.34) 
[1] For once daily (QD) soft gel capsule (SGC), N=165.
Plasma HIV-1 RNA Level 
[Units: Log10 copies/mL]
Mean (Standard Deviation)
 4.92  (0.64)   4.94  (0.67)   5.04  (0.68)   5.06  (0.64)   4.99  (0.66) 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks   [ Time Frame: Week 8 ]

2.  Primary:   Percentage of Subjects With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/mL at Week 48   [ Time Frame: Week 48 ]

3.  Secondary:   Percentage of Subjects With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Levels < 50 Copies/mL at Week 96   [ Time Frame: Week 96 (End of Study) ]

4.  Secondary:   Mean Change From Baseline to Week 96 in CD4+ T Cell Counts   [ Time Frame: Week 96 (End of Study) ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Frequency Threshold
Threshold above which other adverse events are reported   4.9  

Reporting Groups
  Description
LPV/r 800/200 mg QD Tablet lopinavir/ritonavir 800/200 mg once daily (QD) tablet
LPV/r 400/100 mg BID Tablet lopinavir/ritonavir 400/100 mg twice daily (BID) tablet

Other Adverse Events
    LPV/r 800/200 mg QD Tablet   LPV/r 400/100 mg BID Tablet
Total, other (not including serious) adverse events     
# participants affected / at risk   292/333 (87.69%)   287/331 (86.71%) 
Gastrointestinal disorders     
Abdominal pain † 1     
# participants affected / at risk   26/333 (7.81%)   28/331 (8.46%) 
Abdominal pain upper † 1     
# participants affected / at risk   22/333 (6.61%)   16/331 (4.83%) 
Diarrhea † 1     
# participants affected / at risk   210/333 (63.06%)   197/331 (59.52%) 
Dyspepsia † 1     
# participants affected / at risk   21/333 (6.31%)   9/331 (2.72%) 
Flatulence † 1     
# participants affected / at risk   17/333 (5.11%)   27/331 (8.16%) 
Nausea † 1     
# participants affected / at risk   105/333 (31.53%)   84/331 (25.38%) 
Vomiting † 1     
# participants affected / at risk   46/333 (13.81%)   46/331 (13.90%) 
General disorders     
Asthenia † 1     
# participants affected / at risk   25/333 (7.51%)   18/331 (5.44%) 
Fatigue † 1     
# participants affected / at risk   45/333 (13.51%)   37/331 (11.18%) 
Influenza like illness † 1     
# participants affected / at risk   9/333 (2.70%)   19/331 (5.74%) 
Pyrexia † 1     
# participants affected / at risk   28/333 (8.41%)   29/331 (8.76%) 
Infections and infestations     
Bronchitis † 1     
# participants affected / at risk   29/333 (8.71%)   26/331 (7.85%) 
Gastroenteritis † 1     
# participants affected / at risk   9/333 (2.70%)   19/331 (5.74%) 
Influenza † 1     
# participants affected / at risk   28/333 (8.41%)   24/331 (7.25%) 
Nasopharyngitis † 1     
# participants affected / at risk   58/333 (17.42%)   61/331 (18.43%) 
Sinusitis † 1     
# participants affected / at risk   19/333 (5.71%)   17/331 (5.14%) 
Upper respiratory tract infection † 1     
# participants affected / at risk   29/333 (8.71%)   25/331 (7.55%) 
Metabolism and nutrition disorders     
Hypercholesterolemia † 1     
# participants affected / at risk   18/333 (5.41%)   19/331 (5.74%) 
Hypertriglyceridemia † 1     
# participants affected / at risk   18/333 (5.41%)   23/331 (6.95%) 
Musculoskeletal and connective tissue disorders     
Back pain † 1     
# participants affected / at risk   21/333 (6.31%)   15/331 (4.53%) 
Nervous system disorders     
Dizziness † 1     
# participants affected / at risk   16/333 (4.80%)   17/331 (5.14%) 
Headache † 1     
# participants affected / at risk   44/333 (13.21%)   33/331 (9.97%) 
Psychiatric disorders     
Anxiety † 1     
# participants affected / at risk   13/333 (3.90%)   18/331 (5.44%) 
Depression † 1     
# participants affected / at risk   18/333 (5.41%)   19/331 (5.74%) 
Insomnia † 1     
# participants affected / at risk   24/333 (7.21%)   27/331 (8.16%) 
Respiratory, thoracic and mediastinal disorders     
Cough † 1     
# participants affected / at risk   32/333 (9.61%)   36/331 (10.88%) 
Pharyngolaryngeal pain † 1     
# participants affected / at risk   14/333 (4.20%)   21/331 (6.34%) 
Skin and subcutaneous tissue disorders     
Pruritus † 1     
# participants affected / at risk   18/333 (5.41%)   14/331 (4.23%) 
Rash † 1     
# participants affected / at risk   27/333 (8.11%)   32/331 (9.67%) 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 11.0



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information